pSivida Corp. (Nasdaq: PSDV) reported positive results from a Phase 3 clinical trial of its eye disease treatment Medidur sending the stock price soaring $1.18 to $4.88.
Upbeat study results for pSivida
December 22, 2015 at 11:18 AM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.